Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Sanofi launches world's first modular concept manufacturing facility to Singapore
Sanofi inaugurated Modulus, a state-of-the-art, sustainable biopharmaceutical manufacturing facility in Singapore, leveraging a modular concept for flexible production of next-generation vaccines and biological medicines, aiming to be fully operational by mid-2026.
Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs
Vir Biotechnology to host virtual investor event on Jan 8, 2025, discussing initial data from Phase 1 T-cell engagers VIR-5818 and VIR-5500, and updates on the PRO-XTEN™ platform.
Patsnap Launches Hiro Life Sciences – Revolutionizing Drug Research with Generative AI
Patsnap launches Hiro Life Sciences (Hiro LS), an AI assistant using PharmaGPT to accelerate biopharmaceutical research by integrating generative AI with domain-specific data, offering real-time insights, seamless integration, enhanced collaboration, and secure interactions.
Hemophilia B Treatment Market 2034: EMA, PDMA, FDA Approvals
Hemophilia B market to grow significantly by 2034, driven by gene therapies like HEMGENIX and BEQVEZ, priced at $3.5 million each. Key companies include Centessa Pharmaceuticals, Sanofi, Pfizer, and Novo Nordisk. Market dynamics influenced by increasing prevalence, prophylactic treatment focus, and pipeline advancements.
SWOT analysis: stock poised for growth amid clinical progress
Vir Biotechnology, a clinical-stage immunology company, focuses on treating serious infectious diseases, particularly hepatitis delta virus (HDV) and hepatitis B virus (HBV). Recent positive Phase 2 data for HDV and HBV treatments have advanced the HDV program to Phase 3 trials. Despite negative earnings per share projections, Vir's strong balance sheet supports long-term growth. The company's strategic partnerships and pipeline expansion into T-cell engagers offer potential market opportunities, though clinical trial risks and commercialization challenges remain.
China's National Reimbursement Drug List (NRDL) outlook for 2024
The National Reimbursement Drug List (NRDL) faces budget pressure and competition, with 445 drugs passing formal review in 2024. Oncology, immunology, neurology, and rare diseases see strategic positioning and comparator choices as key. Contract renewals and re-negotiations are under pressure, emphasizing clear messaging and data preparation for NRDL success.
AffyImmune Names Chief Medical Officer
AffyImmune Therapeutics appoints Deyaa Adib, M.D., as Chief Medical Officer, bringing 28 years of oncology experience. Adib will oversee clinical activities, including strategic direction and execution of development programs. He has led successful registrations in solid tumor and hematologic malignancy indications and has held CMO roles at FibroGen, Triumvira Immunologics, Rain Therapeutics, and Blueprint Medicines.
© Copyright 2025. All Rights Reserved by MedPath